Ashwagandha (KSM-66)
SupplementThe Medical Score (78) is slightly above the Community Score (72), as clinical studies demonstrate consistent efficacy [s1, s2, s6], while community reports more frequently cite long-term side effects such as loss of libido and emotional blunting that are not captured in short RCTs [c2, c3]. The BfR warning from 2024 has noticeably reduced confidence in German forums [s14, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Ashwagandha KSM-66 has the strongest clinical evidence base of any adaptogen: multiple RCTs and two meta-analyses confirm consistent effects on cortisol, sleep, and testosterone — effect sizes are real but modest. The safety profile took a hit in 2024: Germany's BfR explicitly warns of hepatotoxicity risk, and Stiftung Warentest has measurably eroded trust in German-speaking communities. If you use it, cycle it (8–12 weeks on, 4 weeks off), monitor liver enzymes, and stop immediately if emotional blunting or libido loss occurs. Contraindicated with liver disease, pregnancy, and thyroid medication.
Description
Ayurvedic adaptogen (full-spectrum root extract, ≥5% withanolides) with clinical evidence for stress reduction, sleep, cognition, and testosterone [s1, s2, s3].
Ashwagandha (Withania somnifera) is a medicinal plant from Ayurvedic medicine used for millennia in stress, insomnia, exhaustion, and hormonal imbalances [s3]. KSM-66 is a patented full-spectrum root extract (Ixoreal Biomed) standardized to at least 5% withanolides, using exclusively the root—not the leaf [s3, s5]. The extract has been investigated in over 24 clinical studies [s3]. The strongest evidence exists for reduction of perceived stress and cortisol: a placebo-controlled RCT (n=64) demonstrated significantly lower cortisol levels and improved stress management scores after 60 days [s2]. A meta-analysis (2024, n=491) confirmed effects on anxiety and cortisol across multiple studies [s1]. For sleep, a meta-analysis (SMD -0.59; 95% CI -0.75 to -0.42) showed a small but significant effect, particularly pronounced in insomnia patients [s6]. In healthy and sleep-disturbed adults, KSM-66 (300 mg twice daily, 8 weeks) significantly improved sleep onset latency, HAM-A score, and sleep quality [s7]. For cognition, an RCT (n=50, 8 weeks) showed improvements in short- and long-term memory, attention, and information processing speed [s8]. A more recent study (2024) with 600 mg/day demonstrated improvements in cognition, energy, and mood [s9]. In the area of testosterone and muscle strength, an RCT (n=57 young men, 8 weeks resistance training + 600 mg KSM-66/day) showed significant increases in testosterone (+17%), muscle mass, and strength [s10]. For thyroid function, evidence from a small RCT (n=50) in subclinical hypothyroidism showed significant normalization of TSH, T3, and T4 after 8 weeks [s11]. Severe liver damage—including fatalities—has been reported in case reports from India [s12]. The BfR classifies the risk as insufficiently assessable and recommends caution [s14].
Legal Status (DE)
In Germany, ashwagandha (KSM-66) is marketable as a food supplement (NEM) without prescription. The BfR explicitly warned in September 2024 of possible health risks and recommends—together with other European authorities—refraining from taking ashwagandha-containing preparations [s14]. The EMA/HMPC has not established an EU herbal monograph for Withania somnifera [s13]. KSM-66 holds self-affirmed GRAS status in the USA (without FDA review) [s15].
Mechanism of Action
The primary active compounds of KSM-66 are withanolides (steroidal lactones, particularly withanolide D and withaferin A), which act on multiple signaling pathways [s3, s5]: 1. HPA axis and cortisol: Withanolides modulate the activity of the hypothalamic-pituitary-adrenal (HPA) axis and reduce the release of cortisol, the primary stress hormone [s1, s2, s5]. 2. GABAergic system: Withanolides interact with GABA-A receptors and enhance inhibitory neuronal activity, promoting anxiolytic and sleep-inducing effects [s16, s17]. 3. Sympathetic nervous system: Ashwagandha attenuates sympathetic nervous system activity, contributing to stress reduction [s5]. 4. Serotonergic system: Withanolides modulate serotonergic signaling pathways, which may explain mood and cognition effects [s17]. 5. Androgen axis: RCTs have observed increases in testosterone levels and luteinizing hormone (LH), possibly through inhibition of cortisol-induced gonadotropin suppression [s10]. 6. Antioxidant and anti-inflammatory effects: Withanolides inhibit NF-κB signaling pathways and reduce pro-inflammatory cytokines [s3]. 7. Thyroid axis: In an RCT in subclinical hypothyroidism, significant increases in T3 and T4 and normalization of TSH were observed; however, the mechanism has not been fully elucidated [s11].
Dosing
Stressreduktion und Cortisolsenkung
- Dose
- 300 mg 2× daily (600 mg/day) KSM-66 root extract (≥5% withanolides)
- Frequency
- 2× täglich
- Route
- oral
- Duration
- 8–12 Wochen
- Timing
- Morning and evening, with meals
- With food
- empfohlen
Schlafverbesserung
- Dose
- 300 mg 2× daily (600 mg/day) or 300 mg once in the evening
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 8 Wochen
- Timing
- 30 minutes before bedtime (single evening dose) or morning and evening with meals
- With food
- empfohlen
Kognition und Energie
- Dose
- 600 mg/day KSM-66 root extract
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 8 Wochen
- Timing
- With meals
- With food
- empfohlen
Testosteron und Muskelkraft (Männer)
- Dose
- 600 mg/day KSM-66 root extract
- Frequency
- 2× täglich à 300 mg
- Route
- oral
- Duration
- 8 Wochen
- Timing
- With meals, in conjunction with resistance training
- With food
- empfohlen
The BfR has not defined a safe maximum daily dose for ashwagandha, as the available data are considered insufficient [s14]. Clinical studies have used doses up to 600 mg/day KSM-66 for up to 12 weeks [s1, s2, s7]. A long-term study (12 months, 600 mg/day) showed no serious adverse events [s4]; however, case reports do not exclude severe liver damage at undefined doses and durations [s12]. The BfR generally recommends caution [s14].
KSM-66 should be taken with meals, as this improves tolerability [s2]. Intake breaks (e.g., 8–12 weeks on, 4 weeks off) are recommended in the community to avoid tolerance development [c1, c2], but have not been systematically investigated clinically. Pregnant or breastfeeding women, children, and individuals with liver disease should not take ashwagandha [s14].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Durchfall, Magenschmerzen) Reported in a subset of participants in clinical trials; milder than with other herbal extracts and typically self-limiting [s2, s3]. | gelegentlich | leicht |
| Schläfrigkeit, Sedierung GABAergic activation can cause daytime drowsiness, particularly at higher doses or when taken in the morning [s16, s17]. | gelegentlich | leicht |
| Kopfschmerzen, Schwindel Documented as an occasional adverse effect by ÖKO-TEST and clinical studies [s18]. | gelegentlich | leicht |
| Libidoverlust und sexuelle Dysfunktion Frequently mentioned in community reports after 2+ months of continuous use, possibly due to modulation of the estrogen-testosterone balance or excessive cortisol suppression [c2, c3]. Not systematically captured in short-term RCTs. | gelegentlich | moderat |
| Emotionale Abstumpfung ('grey feeling', Anhedonie) Frequently reported in Reddit threads among long-term users; possible association with excessive cortisol or serotonin modulation [c2, c3]. | gelegentlich | moderat |
| Rebound-Angst nach Absetzen Reports of tolerance development and rebound anxiety after prolonged daily use, possibly due to GABA receptor desensitization [c1]. | selten | moderat |
| Erhöhte Schilddrüsenhormone (T3/T4) An RCT in subclinical hypothyroidism showed increases in T3 and T4; problematic in pre-existing hyperthyroidism or concurrent use of thyroid medications [s11]. | selten | moderat |
| Schwere Leberschädigung (Drug-induced Liver Injury, DILI) Multiple case reports from India and internationally, including fatal outcomes. Cholestatic injury patterns have been documented. The BfR classifies this as a relevant risk [s12, s14]. | selten | schwer |
| Hautreaktionen (Ausschlag, Juckreiz) Occasionally described in clinical trials and case reports [s18]. | selten | leicht |
| Schilddrüsenentzündung (Thyreoiditis) Individual case reports of painless thyroiditis following ashwagandha intake have been published [s19]. | selten | schwer |
Contraindications
Ashwagandha has uterotonic properties and may induce uterine contractions; risk of miscarriage. The BfR issues an explicit warning [s14, s18].
Insufficient safety data for infants; BfR recommends abstinence [s14].
BfR recommends against use in children due to lack of safety data [s14].
Multiple case reports of severe hepatotoxicity; BfR warning explicitly applies to patients with hepatic disease [s12, s14].
Immunomodulatory properties may stimulate autoimmune processes; caution advised [s18].
Ashwagandha can increase thyroid hormones (T3, T4) and decrease TSH, which may lead to overdosing in hyperthyroidism or in patients on existing thyroid medication [s11, s18].
Hypotensive and sedative properties may interact with anesthetics; discontinuation at least 2 weeks preoperatively recommended [s18].
Interactions
Synergistic
Theoretical additive stress reduction through complementary mechanisms at the HPA axis and nervous system; clinical data lacking.
Combination potentially synergistic for sleep quality and stress reduction via GABAergic modulation; not clinically investigated.
Both adaptogens complement each other synergistically in stress reduction — Ashwagandha lowers cortisol primarily via the HPA axis, while Rhodiola additionally acts through monoaminergic mechanisms. The combination is frequently used in stress-relief preparations.
Ashwagandha and Bacopa monnieri show synergistic effects on cognitive function and stress reduction in Ayurvedic tradition and preliminary cell studies. Ashwagandha supports stress resilience, while Bacopa promotes memory and neuronal signal transmission.
The combination of Ashwagandha (KSM-66) and melatonin may enhance the sleep-promoting effects of both substances. Ashwagandha reduces stress-related sleep disturbances, while melatonin directly regulates the sleep-wake cycle.
Ashwagandha and Panax Ginseng may complement each other in supporting testosterone, energy, and stress resilience. Both adaptogens act on the HPA axis and hormonal regulation, with Panax Ginseng additionally promoting nitric oxide production.
Shilajit supports direct testosterone production, while Ashwagandha reduces cortisol-mediated inhibition of testosterone production. The combination is considered particularly synergistic for optimizing testosterone levels in men.
The combination of Ashwagandha and L-Theanine is frequently used in sleep and relaxation formulas. Both substances have calming effects and may mutually potentiate stress reduction and sleep promotion.
Ashwagandha and Tulsi (Holy Basil) are traditionally used together as adaptogens in Ayurvedic practice. Both plants act on the HPA axis and may complement each other in stress reduction.
Ashwagandha and Glycine may complement each other in promoting sleep. Ashwagandha reduces stress-related sleep disturbances, while Glycine improves sleep quality by lowering core body temperature.
Caution
Ashwagandha has immunostimulatory properties and may attenuate the effects of immunosuppressants [s18, s20].
Elevation of T3/T4 possible; dose adjustment of thyroid medication required, medical monitoring necessary [s11, s18].
Additive CNS-depressant effect via GABAergic mechanisms; enhanced sedation possible [s18, s20].
Ashwagandha may lower blood glucose; additive effect with antidiabetic agents can lead to hypoglycemia [s14, s18].
Additive antihypertensive effect possible [s14, s18].
Possible interaction via GABAergic modulation; clinical data lacking [s18, s20].
Possible additive effect on blood coagulation; monitoring recommended [s18, s20].
Both Ashwagandha and Berberine can lower blood glucose. Concurrent use may produce an additive hypoglycemic effect, which can trigger hypoglycemia in susceptible individuals.
Rhodiola Rosea has mild MAO-inhibitory activity. In combination with Ashwagandha, which also affects the nervous system, particular caution is warranted when co-administered with antidepressants.
Ashwagandha may increase DHEA and testosterone levels. Concurrent use of exogenous DHEA can lead to additively elevated androgen levels, which may be problematic in hormone-sensitive conditions.
Both Ashwagandha and Enclomiphene influence the hormonal system via the hypothalamic-pituitary-gonadal axis. Concurrent use may result in uncontrolled fluctuations in testosterone and LH levels.
Ashwagandha shares similar mechanisms of action with Metformin via the AMPK pathway and may lower blood glucose. An additive effect with Metformin can lead to excessive blood glucose reduction.
Studies
Tier A — High Evidence
Outcome: Perceived Stress Scale, cortisol, quality of life (SF-36)
Effect Size: Significant cortisol reduction and stress reduction vs. placebo (p<0.05)
Outcome: Overall sleep quality (PSQI, ISI)
Effect Size: SMD=-0.59 (95% CI -0.75 to -0.42; I²=62%)
Outcome: Sleep onset latency (SOL), HAM-A, sleep quality
Effect Size: Significant improvement in SOL (p=0.013), HAM-A (p<0.05), sleep quality (p<0.05)
Outcome: Testosterone, muscle mass, muscle strength (resistance training)
Effect Size: Testosterone +17% vs. placebo (p<0.05)
Outcome: TSH, T3, T4 in subclinical hypothyroidism
Effect Size: TSH p<0.001; T3 p=0.0031; T4 p=0.0096 vs. placebo
Outcome: Anxiety (HAM-A MD=-2.19), stress and serum cortisol (MD=-2.58 ng/mL) vs. placebo
Effect Size: HAM-A MD=-2.19 (95% CI -3.83 to -0.55); cortisol MD=-2.58 (95% CI -4.99 to -0.16)
Outcome: Cognition: memory, attention, information processing
Effect Size: Significant improvement in immediate memory and total memory vs. placebo
Tier B — Moderate Evidence
Outcome: Cognition, energy, mood (600 mg/day)
Effect Size: Significant improvements in cognition, energy, and mood vs. placebo
Outcome: Long-term safety: stress, cortisol, testosterone
Effect Size: Significant reductions in stress and cortisol; no serious adverse events
Tier C — Low Evidence
Outcome: Ashwagandha-induced liver injury (DILI) in India
Effect Size: Severe hepatotoxicity, one fatality documented
Outcome: Painless thyroiditis following ashwagandha intake
Effect Size: Causal relationship suspected, not proven
Community Evidence
Top reported benefits
- Significant stress reduction and improved stress management
- Improved sleep onset and sleep depth
- Increased libido and testosterone with short-term use (≤8 weeks)
- Increased energy and reduced fatigue
- Reduced anxiety and inner calm
Top reported issues
- Loss of libido and sexual dysfunction after 2+ months of continuous use
- Emotional blunting, loss of interest ('grey/flat feeling')
- Tolerance development with long-term daily use
- Rebound anxiety upon discontinuation
- Drowsiness and daytime fatigue
A relevant minority of community users report loss of libido and emotional blunting after 2+ months of daily use, which are not systematically captured in short clinical RCTs [c2, c3]. The BfR warning (September 2024) and reports of liver damage have noticeably reduced confidence in German forums and at Stiftung Warentest [c4, s14]. Some users recommend intake breaks to avoid tolerance [c1].
Scientific Sources
- Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-analysis
Pratte MA, Nanavati KB, Young V, et al. (2024). Complementary Therapies in Medicine (ScienceDirect)APMID:39348746DOI - Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial
Wankhede S, Langade D, Joshi K, et al. (2015). Journal of the International Society of Sports NutritionAPMID:26609282DOI - Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial
Sharma AK, Basu I, Singh S (2018). Journal of Alternative and Complementary MedicineAPMID:28829155DOI - Ashwagandha-induced liver injury—A case series from India
Verma N, Gupta SK, Tiwari S, et al. (2023). Hepatology CommunicationsCDOI - Withaniae somniferae radix – herbal medicinal product (EMA/HMPC assessment)
European Medicines Agency, HMPC (2013). European Medicines AgencyALink - Ashwagandha: Schlafbeeren-Präparate mit möglichen Gesundheitsrisiken (Mitteilung 039/2024)
Bundesinstitut für Risikobewertung (BfR) (2024). BfR – Bundesinstitut für RisikobewertungALink - Ashwagandha: Is It Safe? Part 1: A Regulatory Review
Tandon N, Yadav SS (2024). Phytotherapy ResearchBDOI - Can Ashwagandha Benefit the Endocrine System? A Review (GABA mechanism reference)
Mikulska P, Malinowska M, Ignacyk M, et al. (2023). NutrientsBPMID:38003702DOI - Effects of Withania somnifera on Cortisol Levels in Stressed Human Subjects: A Systematic Review
Pratte MA, Nanavati KB, Young V, et al. (2023). Nutrients / PubMedAPMID:38140274DOI - Ashwagandha: Usefulness and Safety (NCCIH)
National Center for Complementary and Integrative Health (NCCIH) (2023). NCCIH – National Institutes of HealthBLink - Painless Thyroiditis by Withania somnifera (Ashwagandha)
Gagnon A, St-Pierre R, Jabbar A, et al. (2024). BMC Complementary Medicine and Therapies / PMCCDOI - A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults
Chandrasekhar K, Kapoor J, Anishetty S (2012). Indian Journal of Psychological MedicineAPMID:23439798DOI - Ashwagandha Drug Interactions and Contraindications
Wild Foods Co. (2023). Wild Foods Co. / NCCIH cross-referenceDLink - Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis
Pratte MA, Nanavati KB, Young V, et al. (2024). Phytomedicine / PubMedAPMID:39083548DOI - Ashwagandha: Is it helpful for stress, anxiety, or sleep? Health Professional Fact Sheet
Office of Dietary Supplements, NIH (2023). NIH Office of Dietary SupplementsBLink - Long Term Safety and Efficacy of KSM-66 Ashwagandha (ClinicalTrials.gov NCT06244147)
Ixoreal Biomed Inc. (2024). ClinicalTrials.govBLink - Can Ashwagandha Benefit the Endocrine System? A Review
Mikulska P, Malinowska M, Ignacyk M, et al. (2023). Nutrients / PubMedBPMID:38003702DOI - Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis
Cheah KL, Norhayati MN, Husniati Yaacob L, et al. (2021). PLOS ONEAPMID:34559859DOI - Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study
Langade D, Kanchi S, Salve J, et al. (2019). Journal of EthnopharmacologyAPMID:32818573DOI - Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy Adults
Choudhary D, Bhattacharyya S, Bose S (2017). Journal of Dietary SupplementsAPMID:28471731DOI - Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study
Gopukumar K, Bhattacharyya S, Bhattacharyya TK, et al. (2024). Journal of Psychoactive DrugsADOI
Community Sources
Storage
Unopened
Store cool (15–25 °C), dry, and protected from direct sunlight.
Opened
Keep container tightly closed; avoid moisture; powder formulations are particularly moisture-sensitive.
Notes
KSM-66 is a standardized botanical extract; shelf life is typically 2 years from the date of manufacture. Refrigeration is not required, but for capsule formulations, cool storage reduces oxidation.